Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
International Frontier Technology Laboratory Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. At present, the portfolio's active prosecution is limited to 1 pending office action. This matter is being reviewed by 1 distinct examiner, which indicates a highly concentrated point of interaction with the USPTO. Furthermore, the portfolio's current activity is confined to 1 distinct art unit, suggesting that the company's immediate intellectual property efforts are focused on a specific technical sub-field within biotechnology.
The busiest examiner for this portfolio is MARTIN, PAUL C, who is handling the 1 pending office action currently on record. This examiner is the sole official responsible for the company's active examination pipeline. For a practitioner, this means that the success of the current prosecution cycle depends on the dialogue with MARTIN, PAUL C. The presence of 1 busiest examiner pending case reflects a low-volume strategy where each filing is critical. This concentration in 1 distinct art unit allows the legal team to focus their resources on the specific rules and precedents relevant to that single examiner's jurisdiction.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17640657 | Composition Comprising Thermosensitive Gel and Oligopeptide, and Use Thereof | MARTIN, PAUL C | 54d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17640657 | Composition Comprising Thermosensitive Gel and Oligopeptide, and Use Thereof | MARTIN, PAUL C | 1653 | §103 | Final Rejection | 54d | Pending | Sep 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInternational Frontier Technology Laboratory Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul C Martin has the most, with 1 of International Frontier Technology Laboratory Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
